human ptec (ATCC)
Structured Review

Human Ptec, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 4575 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ptec/product/ATCC
Average 99 stars, based on 4575 article reviews
Images
1) Product Images from "Inhibition of cell surface GRP78 and activated α 2M interaction attenuates kidney fibrosis"
Article Title: Inhibition of cell surface GRP78 and activated α 2M interaction attenuates kidney fibrosis
Journal: JCI Insight
doi: 10.1172/jci.insight.183998
Figure Legend Snippet: High glucose– (6 or 24 hours, 30 mM) induced csGRP78 expression, assessed by biotinylation, was increased in ( A ) PTEC ( n = 6) and ( B ) renal fibroblasts ( n = 3). Production of α2M (24 and 48 hours) by PTEC ( C ) and renal fibroblasts ( D ) was increased by high glucose (30 mM, n = 5 and 8, respectively). Similar results were observed for α2M activation ( E and F , respectively) (high glucose 48 hours, 30 mM, n = 5 and 4, respectively). Inhibition of csGRP78 interaction with α2M* using the GRP78-targeting antibody C38 prevented high glucose– (30 mM, 48 hours) induced fibronectin and collagen IV production in both ( G ) PTEC ( n = 4–6) and ( H ) renal fibroblasts ( n = 3–5). Similarly, α2M* inhibition with the Fα2M antibody attenuated matrix protein production in high glucose (30 mM, 48 hours, n = 5–6 PTEC and 4 renal fibroblasts ( I = PTEC and J = renal fibroblasts). Peptide inhibition of the csGRP78/α2M* interaction also prevented matrix protein production in high glucose (30 mM, 48 hours) by ( K ) PTEC ( n = 4–9) and ( L ) renal fibroblasts ( n = 3–6) (* P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001).
Techniques Used: Expressing, Activation Assay, Inhibition
Figure Legend Snippet: TGF-β1 (5 ng/mL, 6 or 24 hours) increased localization of GRP78 to the surface of both PTEC and renal fibroblasts, assessed by biotinylation ( A and B , respectively) ( n = 4). Similarly, TGF-β1– (5 ng/mL) induced α2M production (24 and 48 hours) and activation (48 hours) were increased in PTEC ( n = 6 production and 10 activation) ( C and E ) and renal fibroblasts ( n = 8–9 production and 7 activation) ( D and F ). TGF-β1– (5 ng/mL, 48 hours induced fibronectin and collagen IV production were attenuated by csGRP78 inhibition ( G and H for PTEC and renal fibroblasts, respectively) ( n = 4 for both). Similarly, α2M* inhibition in PTEC and renal fibroblasts prevented TGF-β1-induced matrix protein production ( I and J ) (5 ng/mL, 48 hours, n = 4 and 6) (* P < 0.05, ** P < 0.01, *** P < 0.005; Kruskal-Wallis test used for α2M in D ).
Techniques Used: Activation Assay, Inhibition
Figure Legend Snippet: High glucose– (30 mM, 48 hours) induced activation of Smad3 (measured as phosphorylation at Ser473/475) was prevented by csGRP78 inhibition in PTEC ( n = 3–4) ( A ) and renal fibroblasts ( n = 5) ( B ). Similarly, α2M* inhibition attenuated Smad3 activation by high glucose with either neutralizing antibody ( n = 6 PTEC and 4 renal fibroblasts) ( C = PTEC and D = renal fibroblasts) or inhibitory peptide ( n = 4–5 PTEC and 3–4 renal fibroblasts) ( E = PTEC and F = renal fibroblasts). In both PTEC and renal fibroblasts, csGRP78 (C38, 10 μg) did not prevent TGF-β1– (5 ng/mL, 48 hours) induced Smad3 activation ( n = 4 and 6) ( G and J , respectively). TGF-β1–induced Smad3 activation was also not prevented by α2M* inhibition (Fα2M, 10 μg) in PTEC or renal fibroblasts ( n = 6 for both) ( H and K , respectively). We confirmed these results using the Smad3-mediated reporter CAGA 12 -luciferase. TGF-β1-induced luciferase activation was not prevented by csGRP78 inhibition in either PTEC or renal fibroblasts ( n = 8 for both) ( I and L , respectively). Similarly, inhibition of α2M* did not prevent activation by TGF-β1 ( I and L , respectively) (0.05 ng/mL, 24 hours, n = 8 for both) (* P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.0001; Kruskal-Wallis test used for CAGA 12 -luciferase in K ).
Techniques Used: Activation Assay, Phospho-proteomics, Inhibition, Luciferase
Figure Legend Snippet: Increased YAP and TAZ in response to TGF-β1 (5 ng/mL, 48 hours) were prevented by inhibition of csGRP78 ( n = 4–6 PTEC and 6 renal fibroblasts) ( A = PTEC and B = renal fibroblasts) and α2M* ( n = 4–6 PTEC and 6–8 renal fibroblasts) ( C = PTEC and D = renal fibroblasts). Using the TEAD-luciferase reporter construct, we confirmed that inhibition of both csGRP78 and α2M* in PTEC ( n = 8–10) ( E ) and renal fibroblasts ( n = 7–8) ( F ) prevented YAP/TAZ signaling in response to TGF-β1. High glucose– (30 mM, 48 hours) induced YAP and TAZ expression were also attenuated by csGRP78 ( n = 4 PTEC and 4–6 renal fibroblasts) ( G = PTEC and H = renal fibroblasts) and α2M* ( n = 4–6 PTEC and 4 renal fibroblasts) ( I = PTEC and J = renal fibroblasts) inhibition, as well as by the peptide inhibitor of csGRP78/α2M* interaction ( n = 3–4, PTEC, K ; and n = 4, renal fibroblasts, L ). (* P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.0001.)
Techniques Used: Inhibition, Luciferase, Construct, Expressing
